REG - Smiths Group PLC - Smiths sells 830,000 shares in ICU Medical Inc

SmithsAnnouncement

01/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA0667Fa&default-theme=true

RNS Number : 0667F  Smiths Group PLC  01 March 2024

1 MARCH 2024

 

SMITHS GROUP PLC ('Smiths')

SMITHS GROUP PLC SELLS 830,000 SHARES IN ICU MEDICAL INC

Smiths Group plc confirms that it has sold 830,000 shares in ICU Medical Inc
('ICU Medical'), representing approximately 3.44% of ICU Medical's issued
share capital, and equivalent to approximately 33% of Smiths' holding in ICU
Medical. Smiths will receive net proceeds of c.$88.0m (£69.7m) from the sale
which will be used for general corporate purposes.

 

Smiths continues to hold 1,670,000 shares in ICU Medical representing
approximately 6.92% of ICU Medical's issued share capital.

 

Enquiries:

 

 Investor enquiries                                               Media enquiries
 Siobhán Andrews, Smiths Group                                    Tom Steiner, Smiths Group

 +44 (0)7920 230093                                               +44 (0)7787 415 891

 siobhan.andrews@smiths.com (mailto:siobhan.andrews@smiths.com)   tom.steiner@smiths.com (mailto:tom.steiner@smiths.com)

 Matthew Whyte

 Company Secretary

 +44 (0) 7775 982 879

 Matthew.whyte@smiths.com (mailto:Matthew.whyte@smiths.com)

 

Legal Entity Identifier (LEI): 213800MJL6IPZS3ASA11

 

About Smiths Group

 

For over 170 years, Smiths Group has been pioneering progress by improving our
world through smarter engineering. We serve millions of people every year, to
help create a safer, more efficient, and better-connected world, across four
major global markets:  Energy, General Industry, Safety & Security and
Aerospace. Listed on the London Stock Exchange, Smiths employs more than
15,000 colleagues in over 50 countries. For more information visit
www.smiths.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISSEIEFUELSEIE